Search This Blog

Sunday, April 5, 2026

'Iran Threatens "Complete Utter Annihilation" Of OpenAI's $30B Abu Dhabi Stargate Data Center'

 In a move that may well have been sponsored by Dario Amodei or Elon Musk, Iran's Islamic Revolutionary Guard Corps (IRGC) issued a clear public warning to the US that any damage inflicted on Iran’s power infrastructure will be met with decisive retaliation. Specifically, IRGC spokesperson Brigadier General Ebrahim Zolfaghari threatened the “complete and utter annihilation” of U.S. and Israeli facilities, with Stargate's $30 billion "hidden" AI datacenter in Abu Dhabi singled out as a juicy target for Iranian destruction later in the video.

The threats come on the heels of Iran reportedly delivering enough damage via rocket strikes to some Amazon AWS data centers that they have shut down.

In the video, Zolfaghari warned that “should the USA proceed with its threats concerning Iran’s power plant facilities the following retaliatory measures shall be promptly enacted: All power plants, energy infrastructure, and information and communications technology of the Zionist regime, and all similar companies within the region that have American shareholders shall face complete and utter annihilation.”

As Tom's Hardware notes, after Zolfaghari's remarks end, the video switches to a shot of the Earth from space, which zooms into Abu Dhabi on Google Maps. A zone not far from the coast is then centered on, showing an apparently ‘empty’ area of desert. However, a message is overlaid on this bleak view, stating “Nothing stays hidden to our sight, though hidden by Google.” The video then switches to a ‘night vision’ view of the same area of the map with the full extent of the Stargate AI datacenter in Abu Dhabi clear to see.

The threat comes after the IRGC claimed they targeted Oracle's data centers in Dubai.

There has been no confirmation whether the facility was hit or what damage it may have sustained.

https://www.zerohedge.com/geopolitical/iran-threatens-complete-and-utter-annihilation-openais-30bn-stargate-data-center-abu

Where US gas prices are rising fastest as Trump issues fresh warning to Iran

 Gas prices are continuing to climb as the ongoing conflict with Iran drives up crude oil costs, pushing prices higher at the pump nationwide.


The national average now stands at $4.11 per gallon, up about 86 cents from a month ago, according to AAA. Costs are climbing across nearly every region, with some states already well above the U.S. average.

On the West Coast, drivers are seeing the highest costs, with prices reaching $5.92 per gallon in California and $5.37 in Washington. Meanwhile, on the East Coast, gas prices have surpassed $4 in several areas, including $4.27 in Washington, D.C., and $4.06 in New York. 

Made with Flourish • Create a chart

In the Midwest, Illinois stands out at $4.29 per gallon, while much of the region remains in the mid-$3 range. Southern states remain comparatively cheaper, though prices are rising there as well. Texas and South Carolina are both averaging about $3.82, while Florida is higher at $4.20.

Diesel has climbed to $5.61, up about $1.45 over the past month. As a key fuel for freight, shipping, and public transportation, it is particularly sensitive to refining capacity constraints and global supply disruptions.

In San Francisco, prices have surged even higher. For the first time on record, average diesel costs have surpassed $8 per gallon, according to new data from GasBuddy — marking an unprecedented milestone for any U.S. city.

The climbing fuel costs come as President Donald Trump issued a profanity-laced warning to Iran, giving the regime until Tuesday to allow vessels through the key waterway — or face strikes on its critical infrastructure.

The Strait of Hormuz, a waterway between Iran, the United Arab Emirates and Oman, is a critical energy choke point.

"Open the F----- Strait, you crazy b-------, or you’ll be living in Hell - JUST WATCH!" Trump wrote in a Truth Social post to Iranian leaders.

https://www.foxbusiness.com/politics/where-gas-prices-rising-fastest-trump-issues-fresh-warning-iran

'The Most Honest Health Conversations May Be Those the Law Doesn't Protect'

 Not long ago, a patient came to my ophthalmology clinic for a routine exam. Her eyes were healthy. But when I asked how she was doing, something unspooled. She had been having terrible headaches and was convinced they were connected to her vision. She had already explored this extensively, not on a medical website, but in a weeks-long conversation with ChatGPT, where she had described her headaches, her stress, her sleep, her family history of brain aneurysms, her fear that she was dying. She had shared more with a chatbot than she had ever told any of her doctors.

I'm increasingly hearing versions of this: patients arrive with diagnoses they've workshopped with artificial intelligence (AI), medication concerns shaped by chatbot exchanges, anxieties soothed or amplified in conversations no clinician will ever read. A parallel health narrative is forming outside the medical record, one that is sometimes more complete and often more candid than anything in a patient's "official" chart. Meanwhile, the law Americans assume protects their health privacy mostly does not cover it.

The Health Insurance Portability and Accountability Act (HIPAA) of 1996 applies to information held by doctors, hospitals, health plans, and the business associates working on their behalf. It does not generally apply to consumer AI platforms. As HHS has explained, once a patient directs a covered entity to send data to a third-party app, HIPAA generally does not restrict how that app uses the information unless the app is itself a covered entity or business associate.

In other words, the conversations where patients are most cautious, shaped by the awareness that everything enters a permanent hospital or clinic chart, sit inside a far more developed legal framework. The conversations where they may be most honest sit outside it.

Should HIPAA be extended to cover chatbots like ChatGPT? Yes to the principle, no to the mechanism. Americans urgently need stronger privacy protections when they disclose health information to AI. But stretching a law built for the medical bureaucracy of the late 1990s over every chatbot would be too crude a fix for the problems we actually face.

Consider why patients are building this "shadow" health record in the first place. A chat window at midnight offers something the clinic often cannot: speed, privacy, and no immediate entry into the chart. KFF's latest tracking poll found that one-third of adults used AI for health information or advice in the past year. Four in 10 of those users said they had uploaded personal medical information, such as test results or doctors' notes, into an AI tool, despite the fact that 77% of the public say they are concerned about the privacy of medical information provided to AI tools.

Many of these people are not replacing their doctors. They are telling a chatbot the things they would never say to one. That candor fills a genuine gap, and any serious privacy framework needs to protect it rather than drive it underground.

We already know what happens when it is not protected. The Federal Trade Commission's (FTC) cases against GoodRx and BetterHelp both involved health data beyond HIPAA's reach. In the BetterHelp matter, the FTC alleged the company shared consumers' mental health information for advertising purposes after promising confidentiality. Meanwhile, OpenAI now says explicitly that HIPAA does not apply to ChatGPT Health because it is a consumer wellness product. That honesty is useful. It is not the same thing as enforceable law.

Yet, simply extending HIPAA as written would not solve the problem. HIPAA was engineered for health plans, clearinghouses, and providers. It is notoriously complex even for the institutions it already governs, and it was never designed for systems that generate health inferences from language, behavior, and patterns across sessions.

What we need is a federal rule purpose-built for consumer health AI. The federal government has already begun sketching pieces of this: the FTC's updated Health Breach Notification Rule now clearly reaches many health apps outside HIPAA, and Washington State's My Health My Data Act explicitly covers inferred health data. A national rule should go further. If a platform receives or generates sensitive health information, whether or not it markets itself as a health tool, it should face strict limits on secondary use, real rights to deletion, strong breach notice, and a bright-line prohibition on using health disclosures for targeted advertising without express consent.

But the privacy gap also creates a problem that regulation alone cannot fully solve. We know that many patients withhold medically relevant information from clinicians out of embarrassment, disagreement, or privacy concerns; AI is already becoming a repository for what goes unsaid. When a patient's most revealing disclosures live in a chatbot, the doctor is working from an incomplete picture without knowing it. I have had patients tell me they researched interactions between their glaucoma drops and supplements they never mentioned to their prescribing physician. The full conversation happened with a chatbot, and what reached the medical record was a fragment. The chart was supposed to be the authoritative account of a patient's health. For a growing number of people, it is becoming the redacted one.

There is an irony here that should unsettle those involved in health policy. We spent decades building a legal infrastructure to protect health information inside medicine. In doing so, we drew a bright line around doctors and hospitals -- and we now watch as the most candid health conversations are migrating outside that line. Patients are not going to stop confiding in chatbots; the freedom to be honest without consequence is too valuable. But we owe them more than the current arrangement, in which the law protects their reticence in the exam room far better than their honesty in a chat window.

Henry Bair, MD, MBA, is a resident physician at Wills Eye Hospital and a physician-writer focused on the intersection of health policy and patient care.

https://www.medpagetoday.com/opinion/second-opinions/120645

'Oil and prediction trading unsure after Trump's latest deadline'

 Weekend oil trading and trading on prediction markets of contracts about the Iran war looked hesitant about what President Donald Trump's latest threat will mean for the conflict.

Trump posted Saturday morning that “all hell” will rain down on Iran if Tehran fails to reach a deal and reopen the Strait of Hormuz within 48 hours.

Odds on Kalshi of traffic in the Strait returning to normal by May 15 now remain around where they were before Trump's post at 14%. But odds of opening by June 1 have risen to 30%, up 7 percentage points.

Polymarket showed a mixed reaction. Odds of the conflict ending by May 15 increased to 28% from 25%, while the probability of a resolution by June 30 slipped to 55% from 60%.

Oil outlook

The odds of Brent crude futures (CO1:COM) (BNO) opening above $113.50/bbl Sunday evening after finishing just above $109 Thursday jumped up 21 percentage points to 60%.

IG weekend trading pointed to gains in U.S. oil prices, with WTI moving to just below $108/bbl from around $105 on Thursday. However, a pricing gap remains, with CME WTI futures (CL1:COM) (USO) settling at $111.54/bbl.

There's also a disconnect between the futures contract and the physical price being paid for a barrel of oil. Dated Brent, or the price on barrels bought and sold in the North Sea, topped $140/bbl this past week. That's the highest level since 2008. 

https://www.msn.com/en-us/money/markets/oil-and-prediction-trading-unsure-after-trump-s-latest-deadline/ar-AA20bWG8

Novo Nordisk CEO says weight-loss drug boom has barely begun

 

Pharmaceutical companies have only begun to tap the potential demand for obesity treatments, and expanding access should be a top priority, said Mike Doustdar, the head of Novo Nordisk (NVO), the maker of Wegovy and Ozempic.

Speaking in an interview with the Financial Times, Doustdar said the current reach of these drugs is still limited relative to the scale of need. He said companies in the sector must prioritize broadening availability, noting that tens of millions of people in the United States alone are living with obesity. Despite strong demand, he suggested that only a small fraction of eligible patients are currently being treated, leaving a large untapped population.

He added that even when factoring in competition from Eli Lilly (LLY) and copycat products from compounding pharmacies, the industry is reaching only a modest share of potential users. Much of the conversation, he suggested, has focused on current patients rather than those still outside the system.

Doustdar took over as CEO last year following a challenging stretch for Novo (NVO), during which it ceded market leadership to Eli Lilly (LLY) and faced setbacks in clinical trials. The company is now aiming to regain momentum, including through the rollout of an oral version of Wegovy. However, Eli Lilly (LLY) has also advanced in the same direction, recently securing U.S. approval for its own weight-loss pill, Foundayo.

Improving affordability is central to Novo’s (NVO) strategy. Doustdar said expanding access helped drive the company’s agreement to lower prices for medications distributed through TrumpRx, an initiative backed by the U.S. administration. Other pharmaceutical companies, including Eli Lilly, have struck similar arrangements.

Novo (NVO) is also preparing to reduce U.S. list prices significantly. Wholesale prices for Wegovy are expected to drop by about half, while Ozempic will see a reduction of roughly a third starting next year. According to Doustdar, such pricing moves benefit both policymakers and the company by opening the door to a broader patient base.

At the same time, Novo (NVO) faces growing pressure from patent expirations. The key ingredient in both Ozempic and Wegovy, semaglutide, has recently lost exclusivity in several major markets, including Canada, India, Brazil and China. This has enabled the entry of lower-cost generic alternatives, particularly in India, where multiple companies have already launched competing versions.

Emil Larsen, who oversees Novo’s (NVO) operations outside the U.S., said pricing flexibility will be important in more cost-sensitive regions. The company has already reduced prices for Wegovy injections in India and is prepared to adapt further as competition intensifies.

Larsen noted that the Indian market is becoming increasingly crowded and is likely to grow more competitive in the near term. Novo’s (NVO) goal, he said, is to remain aligned with market pricing as conditions evolve, while continuing to differentiate through product quality and brand reputation.

He said trust plays a crucial role, particularly in emerging markets. Novo’s (NVO) long-standing leadership in insulin, despite decades of generic competition, demonstrates how brand recognition, manufacturing scale and consistent outcomes can sustain market position even after patents expire.

To navigate these challenges, Novo (NVO) has also pursued partnerships. In Brazil, it is working with Eurofarma to market its drugs under new brand names, while in India it has teamed up with Emcure Pharma and Abbott to expand distribution.

Still, Larsen suggested that competition from generics is not the biggest obstacle in some regions. Instead, the more pressing issue is that the market itself remains underdeveloped. In countries like India, he pointed out, relatively few patients are receiving treatment compared with smaller markets such as Denmark.

Ultimately, he said, expanding access will depend heavily on building confidence in established therapies. Strong brands with a track record of delivering reliable outcomes at reasonable prices are likely to play a key role in unlocking growth across emerging markets, the FT reported.

https://seekingalpha.com/news/4572534-novo-nordisk-ceo-says-weight-loss-drug-boom-has-barely-begun

'Iran reports no issues with power supply'

The Iranian energy minister stated that there are no problems in the country with the supply of electricity, amid the ongoing attacks by the United States and Israel.

On the other hand, he recommended that citizens manage their power consumption, as reported by the Islamic Republic of Iran Broadcasting (IRIB).

Earlier on Sunday, US President Donald Trump again threatened to attack Iranian energy infrastructure and "blow up" the country unless Tehran unblocks the Hormuz Strait and reaches an agreement. Iran, however, said it would retaliate against power plants, other key infrastructure, and US businesses across the Middle East if attacked.

https://breakingthenews.net/Article/Iran-reports-no-issues-with-power-supply/66013358

Trump doesn't think ground op will be necessary

 United States President Donald Trump told ABC News on Sunday that he does not think a ground invasion will be necessary in Iran, but that he doesn't rule it out either.

He reaffirmed his earlier threats, stating that "if it happens, it happens. And if it doesn't, we're blowing up the whole country." He stressed that "very little" will be "off limits" if the peace talks fail, while refusing to comment on whether Washington will strike civilian infrastructure. "They don't want to make a deal; their whole country is gone," he once again affirmed.

https://breakingthenews.net/Article/Trump-doesn't-think-ground-op-will-be-necessary/66013339